Serum Ceruloplasmin Levels Correlate Negatively with Liver Fibrosis in Males with Chronic Hepatitis B: A New Noninvasive Model for Predicting Liver Fibrosis in HBV-Related Liver Disease

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zeng, Da Wu ^a   Liu, Yu Rui ^a   Zhang, Jie Min ^a   Zhu, Yue Yong ^a   Lin, Su ^a   You, Jia ^a   Li, You Bing ^a   Chen, Jing ^a   Zheng, Qi ^a   Jiang, Jia Ji ^a   Dong, Jing ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CERULOPLASMIN; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; GLOBIN; PROTHROMBIN;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CERULOPLASMIN BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STAGING; THROMBOCYTE;

ADULT; BIOLOGICAL MARKERS; CERULOPLASMIN; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84886414597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077942     Document Type: Article

References (53)

1. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, et al. (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50(1):: 80-88. doi:10.1016/j.jhep.2008.07.023. PubMed: 18977053.
2. Lee WM, (1997) Hepatitis B virus infection. N Engl J Med 337(24):: 1733-1745. doi:10.1056/NEJM199712113372406. PubMed: 9392700.
3. Liang X, Bi S, Yang W, Wang L, Cui G, et al. (2009) Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine 27(47):: 6550-6557. doi:10.1016/j.vaccine.2009.08.048. PubMed: 19729084.
4. Lok AS, McMahon BJ, (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):: 661-662. doi:10.1002/hep.23190. PubMed: 19714720.
5. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, et al. (2002) Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36(4):: 543-546. doi:10.1016/S0168-8278(02)00004-1. PubMed: 11943427.
6. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, et al. (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35(6):: 1522-1527. doi:10.1053/jhep.2002.33638. PubMed: 12029639.
7. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, et al. (2005) Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54(11):: 1610-1614. doi:10.1136/gut.2005.065136. PubMed: 15871997.
8. Chan HL, Wong GL, Wong VW, (2009) A review of the natural history of chronic hepatitis B in the era of transient elastography. Antiviral Therapy 14: 489-499. PubMed: 19578234.
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, et al. (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2(3):: 263-283. doi:10.1007/s12072-008-9080-3. PubMed: 19669255.
10. EASL clinical practice guidelines (2012) Management of chronic hepatitis B virus infection. J Hepatol 57(1):: 167-185.
11. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, (2009) Liver biopsy. Hepatology 49(3):: 1017-1044. doi:10.1002/hep.22742. PubMed: 19243014.
12. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, et al. (2005) Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 42(6):: 1437-1445. doi:10.1002/hep.20960. PubMed: 16317674.
13. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, et al. (2008) Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 28(10):: 1408-1416. doi:10.1111/j.1478-3231.2008.01784.x. PubMed: 18482268.
14. Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, et al. (2011) A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLOS ONE 6(8):: e23077. doi:10.1371/journal.pone.0023077. PubMed: 21853071.
15. Vallet-Pichard A, Mallet V, Pol S, (2007) FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology 44(3):: 769. PubMed: 16941681.
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patient with hepatitis C virus infection: a prospective study. Lancet 357(9662):: 1069-1075.
17. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38(2):: 518-526. doi:10.1053/jhep.2003.50346. PubMed: 12883497.
18. Rosenberg WM, Voelker M, Thiel R, Becka Nm, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127(6):: 1704-1713. doi:10.1053/j.gastro.2004.08.052. PubMed: 15578508.
19. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, et al. (2005) Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51(10):: 1867-1873. doi:10.1373/clinchem.2005.048389. PubMed: 16055434.
20. Castera L, (2012) Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterologist 142: 1293-1302. doi:10.1053/j.gastro.2012.02.017.
21. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, et al. (2005) A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42(6):: 1373-1381. doi:10.1002/hep.20935. PubMed: 16317693.
22. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, et al. (2003) Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39(2):: 222-230. doi:10.1016/S0168-8278(03)00171-5. PubMed: 12873819.
23. Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, et al. (2005) Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 5: 32. doi:10.1186/1471-230X-5-32. PubMed: 16221307.
24. Holmberg CG, Laurell CB, 7 (1947) I Investigations in serum copper; nature of serum copper and its relation to the iron-binding protein in human serum. Acta Chem Scand 1(10):: 944-950. PubMed: 18876909.
25. Uhlikova E, Kupcova V, Szantova M, Turecky L, (2008) Plasma copper and ceruloplasmin in patients with alcoholic liver steatosis. Bratisl. Lek Listy 109(10):: 431-433.
26. Schaff Z, Lapis K, Szende B, Jeney A, Gergely P, et al. (1991) The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. Exp Pathol 43(1-2):: 111-120. doi:10.1016/S0232-1513(11)80156-8. PubMed: 1783039.
27. Roberts EA, Schilsky ML, (2008) Diagnosis and treatment of Wilson disease: an update. Hepatology 47(6):: 2089-2111. doi:10.1002/hep.22261. PubMed: 18506894.
28. Walshe JM, (2005) Diagnostic significance of reduced serum ceruloplasmin concentration in neurological disease. Mov Disord 20(12):: 1658-1661. doi:10.1002/mds.20628. PubMed: 16092117.
29. Yang X, Tong DJ, Liang J, Zhang YH, Lei JH, et al. (2005) Ceruloplasmin level of patients with liver disease in China. Zhonghua Nei Ke Za Zhi 44(1):: 13-15. PubMed: 15769390.
30. Society of Infectious Diseases and Parasitology and Society of Hepatology, Chinese Medical Association (2000) Chinese Guideline of the Programme of Prevention and Cure for Viral Hepatitis. Zhonghua Gan_Zang_Bing Za_Zhi. 8(6):: 324-329. (in Chinese).
31. Scheuer PJ, Standish RA, Dhillon AP, (2002) Scoring of chronic hepatitis. Clin Liver Dis 6(2):: 335-347, v-vi. doi:10.1016/S1089-3261(02)00009-0. PubMed: 12122859.
32. the French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15-20. doi:10.1002/hep.1840200104. PubMed: 8020885.
33. Sternlieb I, Scheinberg IH, (1961) CERULOPLASMIN IN HEALTH AND DISEASE*. Ann N Y Acad Sci 94(1):: 71-76.
34. Czaja MJ, Weiner FR, Schwarzenberg SJ, Sternlieb I, Scheinberg IH, et al. (1987) Molecular studies of ceruloplasmin deficiency in Wilson's disease. J Clin Invest 80(4):: 1200-1204. doi:10.1172/JCI113180. PubMed: 3654978.
35. Perman JA, Werlin SL, Grand RJ, Watkins JB, (1979) Laboratory measures of copper metabolism in the differentiation of chronic active hepatitis and Wilson disease in children. J Pediatr 94(4):: 564-568. doi:10.1016/S0022-3476(79)80011-6. PubMed: 430291.
36. Walshe JM, JB, (1962) Ceruloplasmin in liver disease. Lancet. vol. ii: 263-265.
37. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, et al. (2006) Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 60(2):: 77-84. PubMed: 16680183.
38. Liu XD, Wu JL, Liang J, Zhang T, Sheng QS, (2012) Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol 18(22):: 2784-2792. doi:10.3748/wjg.v18.i22.2784. PubMed: 22719186.
39. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, et al. (2005) Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 42(2):: 282-292. doi:10.1016/j.jhep.2004.09.007. PubMed: 15986415.
40. Kim SU, Lee JH, Kim, doY, rAhn SH, Jung KSet al (2012) Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLOS ONE 7(5):: e36676. doi:10.1371/journal.pone.0036676. PubMed: 22574212.
41. Chon YE, Choi EH, Song KJ, Park JY, Kim do Y, et al. (2012) Performance of Transient Elastography for the staging of liver fibrosis: a meta-analysis. PLOS ONE 7(9):: e44930. doi:10.1371/journal.pone.oo44930. PubMed: 23049764.
42. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, et al. (2008) Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. J Viral Hepat 15(3):: 179-187. PubMed: 18233991.
43. Livingston SE, Deubner H, Bruden DL, McMahon BJ, Homan CE, et al. (2010) Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. Can J Gastroenterol 24(7):: 445-451. PubMed: 20652161.
44. Aster R, (1966) Pooling of platelets in the spleen: role in the pathogenesis of hypersplenic" thrombocytopenia. Journal of Clinical Investigation 45(5):: 645.
45. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, et al. (2003) Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 98(11):: 2516-2520. doi:10.1111/j.1572-0241.2003.08665.x. PubMed: 14638357.
46. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, et al. (1999) Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 94(7):: 1918-1922. doi:10.1111/j.1572-0241.1999.01231.x. PubMed: 10406260.
47. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, et al. (2006) APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 40(6):: 535-542. doi:10.1097/00004836-200607000-00013. PubMed: 16825937.
48. Lee IC, Chan CC, Huang YH, Huo TI, Chu CJ, et al. (2011) Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e antigen-negative chronic hepatitis B. J Clin Gastroenterol 45(3):: 278-285. doi:10.1097/MCG.0b013e3181dd5357. PubMed: 20505530.
49. Kim SM, Sohn JH, Kim TY, Roh YW, Eun CS, et al. (2009) Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease. Korean J Hepatol15(4):: 454-463. doi:10.3350/kjhep.2009.15.4.454. PubMed: 20037264.
50. Tong MJ, Hsu L, Hsien C, Kao JH, Durazo FA, et al. (2010) A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int 4(2):: 516-522. doi:10.1007/s12072-010-9179-1. PubMed: 20827410.
51. Park SH, Kim CH, Kim DJ, Cheong JY, Cho SW, et al. (2011) Development and validation of a model to predict advanced fibrosis in chronic hepatitis B virus-infected patients with high viral load and normal or minimally raised ALT. Dig Dis Sci 56(6):: 1828-1834. doi:10.1007/s10620-010-1477-x. PubMed: 21086167.
52. Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE, et al. (2011) Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 46(7-8):: 962-972. doi:10.3109/00365521.2011.574725. PubMed: 21623677.
53. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J, (2005) Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 128(4):: 1146-8; author reply 10.1053/j.gastro.2005.02.056. PubMed: 15825108.